Changyi Quan, MD
Tianjin Medical University Second Hospital
Emerging Leaders
#3826 pts
Current Leaders
#3,6297 pts
All-Time Leaders
#47126 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2022. 5 trials as lead/chair. How it works →
Trials led — by scientific impact
Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial
N/ARecruitingTianjin Medical University Second Hospital
8
impact
A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma
Phase 2RecruitingTianjin Medical University Second Hospital
8
impact
Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma: A Prospective, Open-Label, Multicenter, Randomized Controlled Trial
N/ARecruitingTianjin Medical University Second Hospital
7
impact
A Prospective Single-arm Clinical Study of Pembrolizumab Combined With Lenvatinib Neoadjuvant Therapy in Patients With Advanced Renal Cell Carcinoma
Phase 2CompletedTianjin Medical University Second Hospital
3
impact
A Single-arm Study of the Efficacy of Tislelizumab Combined With Lenvatinib in Patients With Stage III-IV Renal Cancer
Phase 2UnknownTianjin Medical University Second Hospital
0
impact